Bucindolol displays intrinsic sympathomimetic activity in human myocardium

P. Andréka, Nambi Aiyar, Leslie C. Olson, Jian Qin Wei, Mark S. Turner, Keith A. Webster, Eliot H. Ohlstein, Nanette H. Bishopric

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background - Most clinical studies have shown that β-adrenergic receptor antagonists improve long-term survival in heart failure patients. Bucindolol, a nonselective β-receptor blocker, however, failed to reduce heart failure mortality in a recent large clinical trial. The reasons for this failure are not known. Bucindolol has partial agonist properties in rat myocardium, but whether it has agonist activity in human heart is controversial. To address this, we measured the ability of bucindolol to increase cAMP accumulation in human myocardium. Methods and Results - Myocardial strips (≈ 1 mm3) obtained from rat and nonfailing human hearts were confirmed to be viable for ≥48 hours in normoxic tissue culture by MTT assay and histology. Freshly isolated strips were exposed to β-adrenergic antagonists and agonists and assayed for cAMP. In both rat and human strips, the full β-adrenergic agonist isoproterenol raised cAMP levels by >2.5-fold at 15 minutes. Carvedilol and propranolol had no effect on basal cAMP levels, whereas metoprolol reduced basal cAMP by ≈25%. In contrast, bucindolol and xamoterol increased cAMP levels in a concentration-dependent manner in both rat and human myocardium (maximum 1.64±0.25-fold and 2.00±0.27-fold over control, respectively, P

Original languageEnglish
Pages (from-to)2429-2434
Number of pages6
JournalCirculation
Volume105
Issue number20
DOIs
Publication statusPublished - May 21 2002

Fingerprint

Sympathomimetics
Human Activities
Myocardium
Adrenergic Agonists
Adrenergic Antagonists
Xamoterol
Heart Failure
Metoprolol
Isoproterenol
Propranolol
Histology
Clinical Trials
Survival
Mortality
bucindolol

Keywords

  • Bucindolol
  • Heart failure
  • Pharmacology
  • Receptors
  • Xamoterol

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Andréka, P., Aiyar, N., Olson, L. C., Wei, J. Q., Turner, M. S., Webster, K. A., ... Bishopric, N. H. (2002). Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation, 105(20), 2429-2434. https://doi.org/10.1161/01.CIR.0000016050.79810.18

Bucindolol displays intrinsic sympathomimetic activity in human myocardium. / Andréka, P.; Aiyar, Nambi; Olson, Leslie C.; Wei, Jian Qin; Turner, Mark S.; Webster, Keith A.; Ohlstein, Eliot H.; Bishopric, Nanette H.

In: Circulation, Vol. 105, No. 20, 21.05.2002, p. 2429-2434.

Research output: Contribution to journalArticle

Andréka, P, Aiyar, N, Olson, LC, Wei, JQ, Turner, MS, Webster, KA, Ohlstein, EH & Bishopric, NH 2002, 'Bucindolol displays intrinsic sympathomimetic activity in human myocardium', Circulation, vol. 105, no. 20, pp. 2429-2434. https://doi.org/10.1161/01.CIR.0000016050.79810.18
Andréka, P. ; Aiyar, Nambi ; Olson, Leslie C. ; Wei, Jian Qin ; Turner, Mark S. ; Webster, Keith A. ; Ohlstein, Eliot H. ; Bishopric, Nanette H. / Bucindolol displays intrinsic sympathomimetic activity in human myocardium. In: Circulation. 2002 ; Vol. 105, No. 20. pp. 2429-2434.
@article{995db27ef056488ab2e9f89776ebba5a,
title = "Bucindolol displays intrinsic sympathomimetic activity in human myocardium",
abstract = "Background - Most clinical studies have shown that β-adrenergic receptor antagonists improve long-term survival in heart failure patients. Bucindolol, a nonselective β-receptor blocker, however, failed to reduce heart failure mortality in a recent large clinical trial. The reasons for this failure are not known. Bucindolol has partial agonist properties in rat myocardium, but whether it has agonist activity in human heart is controversial. To address this, we measured the ability of bucindolol to increase cAMP accumulation in human myocardium. Methods and Results - Myocardial strips (≈ 1 mm3) obtained from rat and nonfailing human hearts were confirmed to be viable for ≥48 hours in normoxic tissue culture by MTT assay and histology. Freshly isolated strips were exposed to β-adrenergic antagonists and agonists and assayed for cAMP. In both rat and human strips, the full β-adrenergic agonist isoproterenol raised cAMP levels by >2.5-fold at 15 minutes. Carvedilol and propranolol had no effect on basal cAMP levels, whereas metoprolol reduced basal cAMP by ≈25{\%}. In contrast, bucindolol and xamoterol increased cAMP levels in a concentration-dependent manner in both rat and human myocardium (maximum 1.64±0.25-fold and 2.00±0.27-fold over control, respectively, P",
keywords = "Bucindolol, Heart failure, Pharmacology, Receptors, Xamoterol",
author = "P. Andr{\'e}ka and Nambi Aiyar and Olson, {Leslie C.} and Wei, {Jian Qin} and Turner, {Mark S.} and Webster, {Keith A.} and Ohlstein, {Eliot H.} and Bishopric, {Nanette H.}",
year = "2002",
month = "5",
day = "21",
doi = "10.1161/01.CIR.0000016050.79810.18",
language = "English",
volume = "105",
pages = "2429--2434",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "20",

}

TY - JOUR

T1 - Bucindolol displays intrinsic sympathomimetic activity in human myocardium

AU - Andréka, P.

AU - Aiyar, Nambi

AU - Olson, Leslie C.

AU - Wei, Jian Qin

AU - Turner, Mark S.

AU - Webster, Keith A.

AU - Ohlstein, Eliot H.

AU - Bishopric, Nanette H.

PY - 2002/5/21

Y1 - 2002/5/21

N2 - Background - Most clinical studies have shown that β-adrenergic receptor antagonists improve long-term survival in heart failure patients. Bucindolol, a nonselective β-receptor blocker, however, failed to reduce heart failure mortality in a recent large clinical trial. The reasons for this failure are not known. Bucindolol has partial agonist properties in rat myocardium, but whether it has agonist activity in human heart is controversial. To address this, we measured the ability of bucindolol to increase cAMP accumulation in human myocardium. Methods and Results - Myocardial strips (≈ 1 mm3) obtained from rat and nonfailing human hearts were confirmed to be viable for ≥48 hours in normoxic tissue culture by MTT assay and histology. Freshly isolated strips were exposed to β-adrenergic antagonists and agonists and assayed for cAMP. In both rat and human strips, the full β-adrenergic agonist isoproterenol raised cAMP levels by >2.5-fold at 15 minutes. Carvedilol and propranolol had no effect on basal cAMP levels, whereas metoprolol reduced basal cAMP by ≈25%. In contrast, bucindolol and xamoterol increased cAMP levels in a concentration-dependent manner in both rat and human myocardium (maximum 1.64±0.25-fold and 2.00±0.27-fold over control, respectively, P

AB - Background - Most clinical studies have shown that β-adrenergic receptor antagonists improve long-term survival in heart failure patients. Bucindolol, a nonselective β-receptor blocker, however, failed to reduce heart failure mortality in a recent large clinical trial. The reasons for this failure are not known. Bucindolol has partial agonist properties in rat myocardium, but whether it has agonist activity in human heart is controversial. To address this, we measured the ability of bucindolol to increase cAMP accumulation in human myocardium. Methods and Results - Myocardial strips (≈ 1 mm3) obtained from rat and nonfailing human hearts were confirmed to be viable for ≥48 hours in normoxic tissue culture by MTT assay and histology. Freshly isolated strips were exposed to β-adrenergic antagonists and agonists and assayed for cAMP. In both rat and human strips, the full β-adrenergic agonist isoproterenol raised cAMP levels by >2.5-fold at 15 minutes. Carvedilol and propranolol had no effect on basal cAMP levels, whereas metoprolol reduced basal cAMP by ≈25%. In contrast, bucindolol and xamoterol increased cAMP levels in a concentration-dependent manner in both rat and human myocardium (maximum 1.64±0.25-fold and 2.00±0.27-fold over control, respectively, P

KW - Bucindolol

KW - Heart failure

KW - Pharmacology

KW - Receptors

KW - Xamoterol

UR - http://www.scopus.com/inward/record.url?scp=0037150153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037150153&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000016050.79810.18

DO - 10.1161/01.CIR.0000016050.79810.18

M3 - Article

VL - 105

SP - 2429

EP - 2434

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 20

ER -